Evolus Inc (EOLS) Stock Price, Quote & News

Company Profile

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 949 284 4555

Website: www.evolus.com

Address:

520 Newport Center Drive, Suite 1200, Newport Beach, United States

goofyfoot Jul. 30 at 6:05 PM

$EOLS is going to announce earnings on Tuesday, August 5, after the market closes. A $0.098/share loss is expected, which is an improvement over last quarter’s $0.15/share loss.

0 · Reply

DJebay Jul. 27 at 3:44 AM

$EOLS being shorted like crazy before earnings? So odd

1 · Reply

Allf2 Jul. 26 at 1:27 AM

$EOLS It was a day of doubt about investing in this stock. In Korea, Botox plastic surgery to remove cheek fat was popular and is still ongoing due to v-line marketing. If there is a trend in the US that prefers sharp jaws someday, Botox treatment will be more popular. The market situation that is focused on getting rid of wrinkles is a bit frustrating. Even the market growth forecast has decreased!

0 · Reply

goofyfoot Jul. 25 at 7:51 PM

$EOLS Strange moves today. The bottom almost fell out, followed by a quick recovery. Hmmm…

0 · Reply

Allf2 Jul. 25 at 3:27 PM

$EOLS oooops

1 · Reply

EricKuoTW Jul. 24 at 6:06 PM

$EOLS

0 · Reply

DCRMIA Jul. 24 at 1:45 PM

$EOLS much more is about to come

1 · Reply

Allf2 Jul. 23 at 12:30 AM

$EOLS start

0 · Reply

goofyfoot Jul. 17 at 11:14 PM

$EOLS $EOLS Let’s get this puppy cooking. The ER is the 30th, according to Yahoo!

0 · Reply

Mandi63 Jul. 15 at 1:44 PM

$AEON $CDLI $INKT $LENZ $AEON Next month $2-5 $EOLS EUROPEAN PARTNERS ALREADY SELLING THIS DRUG

0 · Reply

Evolus to Report Second Quarter Financial Results on August 5, 2025

Jul 21, 2025, 5:20 PM EDT - 9 days ago

Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings

Jul 11, 2025, 4:05 PM EDT - 19 days ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 9, 2025, 8:00 AM EDT - 21 days ago

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France

Jun 10, 2025, 8:00 AM EDT - 7 weeks ago

Evolysse™ Recognized in 2025 Shape Skin Awards

May 27, 2025, 4:15 PM EDT - 2 months ago

Evolus Announces Departure of its Chief Financial Officer

May 22, 2025, 8:00 AM EDT - 2 months ago

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

May 7, 2025, 7:13 PM EDT - 3 months ago

Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 3 months ago

Evolus Reports First Quarter 2025 Results

May 5, 2025, 4:05 PM EDT - 3 months ago

Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

Apr 23, 2025, 8:00 AM EDT - 3 months ago

Evolus to Report First Quarter Financial Results on May 7, 2025

Apr 16, 2025, 8:00 AM EDT - 3 months ago

Evolus Announces Commercial Launch of Evolysse™

Apr 15, 2025, 8:00 AM EDT - 3 months ago

Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels

Mar 25, 2025, 8:00 AM EDT - 4 months ago

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Mar 4, 2025, 11:18 PM EST - 5 months ago

Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 4:17 PM EST - 5 months ago

Evolus posts quarterly profit on strong sales of cosmetic injection

Mar 4, 2025, 4:05 PM EST - 5 months ago

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

Feb 27, 2025, 8:00 AM EST - 5 months ago

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Feb 20, 2025, 8:00 AM EST - 5 months ago

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Feb 18, 2025, 8:00 AM EST - 5 months ago

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

Feb 13, 2025, 1:45 PM EST - 5 months ago

US FDA approves Evolus' anti-wrinkle gels

Feb 13, 2025, 1:30 PM EST - 5 months ago

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Jan 21, 2025, 8:00 AM EST - 6 months ago

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance

Jan 14, 2025, 2:00 PM EST - 7 months ago

Evolus: Still Bullish, But Business Faces Tricky Challenges In '25

Nov 6, 2024, 7:28 PM EST - 9 months ago

Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript

Nov 6, 2024, 4:05 PM EST - 9 months ago

Evolus Reports Third Quarter 2024 Results

Nov 1, 2024, 8:00 AM EDT - 9 months ago

Evolus to Participate in Stifel 2024 Healthcare Conference

Oct 31, 2024, 2:02 PM EDT - 9 months ago

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Oct 29, 2024, 8:00 AM EDT - 9 months ago

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Oct 23, 2024, 8:00 AM EDT - 10 months ago

Evolus to Report Third Quarter Financial Results on November 6, 2024

Sep 6, 2024, 8:00 AM EDT - 11 months ago

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Jul 31, 2024, 10:22 PM EDT - 1 year ago

Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 4:09 PM EDT - 1 year ago

Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rival

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Jul 31, 2024, 8:00 AM EDT - 1 year ago

Evolus to Hold Investor Day on September 12, 2024

Jul 30, 2024, 8:00 AM EDT - 1 year ago

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

Evolus to Report Second Quarter Financial Results on July 31, 2024

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Evolus Announces Appointment of Albert G. White III to Board of Directors

Jun 24, 2024, 8:00 AM EDT - 1 year ago

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain

May 22, 2024, 7:00 AM EDT - 1 year ago

Evolus: Chiseling Away At The Aesthetic Market

May 20, 2024, 8:30 AM EDT - 1 year ago

Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

May 15, 2024, 8:30 AM EDT - 1 year ago

Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women's Wear Daily Beauty CEO Summit

May 10, 2024, 9:10 AM EDT - 1 year ago

Evolus' Sandra Beaver Named Orange County Business Journal's Public Company CFO of the Year

May 7, 2024, 11:27 PM EDT - 1 year ago

Evolus, Inc. (EOLS) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 1 year ago

Evolus Reports First Quarter 2024 Results and Provides Business Update

Apr 23, 2024, 4:30 PM EDT - 1 year ago

Evolus to Report First Quarter Financial Results on May 7, 2024

Apr 17, 2024, 4:05 PM EDT - 1 year ago

Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference

goofyfoot Jul. 30 at 6:05 PM

$EOLS is going to announce earnings on Tuesday, August 5, after the market closes. A $0.098/share loss is expected, which is an improvement over last quarter’s $0.15/share loss.

0 · Reply

DJebay Jul. 27 at 3:44 AM

$EOLS being shorted like crazy before earnings? So odd

1 · Reply

Allf2 Jul. 26 at 1:27 AM

0 · Reply

goofyfoot Jul. 25 at 7:51 PM

$EOLS Strange moves today. The bottom almost fell out, followed by a quick recovery. Hmmm…

0 · Reply

Allf2 Jul. 25 at 3:27 PM

$EOLS oooops

1 · Reply

EricKuoTW Jul. 24 at 6:06 PM

$EOLS

0 · Reply

DCRMIA Jul. 24 at 1:45 PM

$EOLS much more is about to come

1 · Reply

Allf2 Jul. 23 at 12:30 AM

$EOLS start

0 · Reply

goofyfoot Jul. 17 at 11:14 PM

$EOLS $EOLS Let’s get this puppy cooking. The ER is the 30th, according to Yahoo!

0 · Reply

Mandi63 Jul. 15 at 1:44 PM

$AEON $CDLI $INKT $LENZ $AEON Next month $2-5 $EOLS EUROPEAN PARTNERS ALREADY SELLING THIS DRUG

0 · Reply

Mandi63 Jul. 10 at 1:14 PM

$AEON Slow move to $1-2 then when results announced $5-10 any shares needed to sale will be higher priced a less dilution…new CEO new VISION 25 years experience FDA UPCOMING IS BROAD DECISION EUROPEAN PARTNER $EOLS ALREADY SELLING THIS DRUG INSIDE BUYING SUPER LOW FLOAT ECT DO YOUR OWN RESEACH

0 · Reply

junebug67 Jul. 9 at 3:27 PM

$EOLS

0 · Reply

junebug67 Jul. 8 at 4:13 PM

$EOLS

0 · Reply

Mandi63 Jul. 2 at 8:13 AM

$AEON $EOLS

0 · Reply

DCRMIA Jun. 28 at 11:06 PM

$EOLS is getting hot, and it's gonna blow up next week. You'll see.

0 · Reply

Mandi63 Jun. 25 at 12:21 PM

$AEON Already approved..drug..selling though international partner $EOLS FDA APPROVAL COMING…OR BUYOUT $10.00-25.00

0 · Reply

Olena Jun. 23 at 11:42 PM

$AEON $EOLS ready!

0 · Reply

Culby Jun. 17 at 2:28 PM

$EOLS what’s keeping this in this $9 range? Everytime it looks like it’s gonna start to move it gets stomped back down.

1 · Reply

Mandi63 Jun. 13 at 5:30 PM

$AEON LOOK FOR A STRONG CLOSE…HEADED FOR THE WEEKEND…FDA MEETING…DATA PRESENTED INSIDE BUYING…SHARES BEING LOCKED Up …JOREY CHERNETT BOUGHT 1,250,000 PLUS SHARE… THREE CONFIRMED 5% SHAREHOLDERS….ALREADY APPROVED DRUG BEING SOLD THOUGH INTERNATIONAL PARTNER $EOLS….LOOK FOR FAST-TRACK APPROVAL…

0 · Reply

Mandi63 Jun. 12 at 12:41 PM

$AEON ALREADY APPROVED DRUG…NATIONAL PARTNER $EOLS FDA MEETING COMING WITH DATA RESULTS SHAREHOLDER MEETING TOMORROW….$1.00 PLUS INSIDE BUYING NEW CEO WITH 25 YEARS EXPERIENCE INVOLVED WITH MERGER BUYOUT $10.00 PLUS

1 · Reply

Mandi63 Jun. 11 at 5:06 PM

$AEON Clearpath CEO JOREY Chernett bought. 10% of AEON.. Inside buying with last date 5/21 National Partner $EOLS $5.00-25.00 price target $360.00

0 · Reply

Rossumopossum Jun. 11 at 1:46 PM

$EOLS lets see this thing go today. Its overdue imo nfa

1 · Reply

Market Cap	598.34M
Revenue (ttm)	266.27M
Net Income (ttm)	-50.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-18.94%
Debt to Equity Ratio	-18.46

Volume	1,393,400
Avg Vol	1,003,846
Day's Range	N/A - N/A
Shares Out	64.48M
Stochastic %K	21%
Beta	0.97
Analysts	Strong Sell
Price Target	$24.17